Christopher U. Cates, MD

Debulking for In-Stent Restenosis in the Brachytherapy Era: Does it Still Have a Role?

08/01/2008

Ajay Tuli , MD;

Veerappan Subramaniyam , MD;

Stephen Bakir , MD;

Peter C. Block , MD;

Ian R. Crocker , MD;

Christopher U. Cates , MD;

Key words: angioplasty, brachytherapy, laser, restenosis Trials comparing coronary artery stenting to coronary artery bypass grafting (CABG) have shown that repeat revascularization continues to be the main limitation of percutaneous...

Key words: angioplasty,...

08/01/2008

Journal of Invasive Cardiology

Commentary

Preventing Restenosis with Stent Drug Coatings

08/01/2008

Kirk N. Garratt , MD, MSc;

Tim A. Fischell , MD, FACC, FSCAI;

Jorge A. Belardi , MD, PhD;

Christopher U. Cates , MD;

Philip Walker , MD;

Roberto Falotico , MD;

Uncertainties with Drug-Eluting Stents Percutaneous coronary revascularization is a worldwide accepted technique as part of the treatment of coronary artery disease. Despite the use of stents, restenosis continues to be the major limitation...

Uncertainties with Drug-Eluting...

08/01/2008

Journal of Invasive Cardiology

Feature

IAGS Proceedings - <br />
Troubling Lesion Subsets: Bifurcation Disease

08/01/2008

Brian O'Murchu , MD;

Howard A. Cohen , MD;

Hal Whitworth ;

Jeffrey Werner , MD;

Michael Cowley , MD;

Alfredo E. Rodriguez , MD, PhD;

James P. Zidar , MD;

Raoul Bonan , MD;

Kirk N. Garratt , MD, MSc;

Max Amor , MD;

Tom J. Linnemeier , MD;

Christopher U. Cates , MD;

Moderator: Kirk Garratt Panel Members: Tom Linnemeier, Brian O’Murchu, Jeffrey Werner Tom Linnemeier: The best treatment option today for a true LAD diagonal bifurcation lesion is to place a stent in the LAD and dilate through the...

Moderator: Kirk Garratt Panel...

08/01/2008

Journal of Invasive Cardiology

IAGS (International Andreas Gruentzig Society) Proceedings

Drug-Eluting Stents: Current Limitations

08/01/2008

Jamey Jacobs ;

Tim A. Fischell , MD, FACC, FSCAI;

Jorge A. Belardi , MD, PhD;

Christopher U. Cates , MD;

Alfredo E. Rodriguez , MD, PhD;

Gregory Braden , MD;

Mike Cowley , MD;

David Sperling , MD;

Robert Fischell , MD;

Mike Cowley: Let’s begin with discussing case selection. Which patients should receive drug-eluting stents (DES)? Should they only receive one stent? Should we reserve DES for a select patient population? What should the approach be for...

Mike Cowley: Let’s begin with...

08/01/2008

Journal of Invasive Cardiology

IAGS (International Andreas Gruentzig Society) Proceedings

Stroke Prevention and Therapies

08/01/2008

Renato DeRita , MS;

Barry S. George , MD, FACC, FSCAI;

Fayaz Shawl , MD;

Christopher U. Cates , MD;

Michael R. Mooney , MD;

Jiri J. Vitek , MD, PhD;

Norberto Schechtmann , MD;

Barry George: Needless to say, Fayaz, you have a bias against distal protection, and it’s an emotional issue for those of us who do carotid stenting. Fayaz Shawl: I am not biased, I just think a randomized trial is needed. Barry George: I...

Barry George: Needless to say,...

08/01/2008

Journal of Invasive Cardiology